Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

1. Rituximab (Riximyo) - Non?Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Rheumatoid Arthritis

Rituximab (Riximyo) - Non?Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Rheumatoid Arthritis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2020 Health Canada - Drug and Health Product Register

2. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data Full Text available with Trip Pro

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) navigation Ann Rheum Dis Actions . 2020 Aug 5;annrheumdis-2019-216761. doi: 10.1136/annrheumdis-2019-216761. Online ahead of print. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Rheumatology Clinical Research Division, Swedish Medical Center/Providence St. Joseph Health and University

2020 EvidenceUpdates

3. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis Full Text available with Trip Pro

Infections in baricitinib clinical trials for patients with active rheumatoid arthritis Infections in baricitinib clinical trials for patients with active rheumatoid arthritis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Ann Rheum Dis Actions . 2020 Oct;79(10):1290-1297. doi: 10.1136/annrheumdis-2019-216852. Epub 2020 Aug 11. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis

2020 EvidenceUpdates

4. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial

Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) : 10.1093/rheumatology/keaa234. Online ahead of print. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Rheumatology, Medical University of Vienna, Vienna, Austria. 2 Department of Rheumatology, Metroplex Clinical Research Center, Dallas, TX, USA. 3 Department of Internal Medicine, Rheumatology/Clinical Immunology, University Hospital

2020 EvidenceUpdates

5. Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis

Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis Evidence summary Published: 21 July 2020 www.nice.org.uk/guidance/es29 pathways Product overview Product overview The content of this evidence summary was up-to-date in July 2020. See summaries of product characteristics (SPCs), British National Formulary (BNF) or the Medicines and Healthcare products Regulatory (...) Agency (MHRA) or NICE websites for up-to-date information. Remsima for subcutaneous injection (Celltrion Healthcare Hungary Kft) is a biosimilar monoclonal antibody of infliximab that inhibits the activity of tumour necrosis factor (TNF)-alpha. It has a marketing authorisation for managing rheumatoid arthritis in combination with methotrexate. Likely place in therapy Likely place in therapy As with all biologic disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis, Remsima

2020 National Institute for Health and Clinical Excellence - Advice

6. Rituximab (Ruxience) - Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA)

Rituximab (Ruxience) - Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent

2020 Health Canada - Drug and Health Product Register

7. Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab

Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab Implication of Baseline Levels and Early Changes of C-reactive Protein for Subsequent Clinical Outcomes of Patients With Rheumatoid Arthritis Treated With Tocilizumab - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Ann Rheum Dis Actions . 2020 Jul;79(7):874-882. doi: 10.1136/annrheumdis-2019-215987. Epub 2020 May 5. Implication of Baseline Levels and Early Changes of C-reactive Protein for Subsequent Clinical Outcomes of Patients With Rheumatoid Arthritis Treated With Tocilizumab , , , Affiliations Expand Affiliations

2020 EvidenceUpdates

8. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study Full Text available with Trip Pro

Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study Efficacy and Safety of Upadacitinib in Japanese Patients With Rheumatoid Arthritis (SELECT-SUNRISE): A Placebo-Controlled Phase IIb/III Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Rheumatology (Oxford) Actions . 2020 Apr 11;keaa084. doi: 10.1093/rheumatology/keaa084. Online ahead of print. Efficacy and Safety of Upadacitinib in Japanese Patients With Rheumatoid Arthritis (SELECT-SUNRISE): A Placebo-Controlled Phase IIb/III Study , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Internal Medicine, Toho University

2020 EvidenceUpdates

9. Upadacitinib (Rinvoq) - rheumatoid arthritis

Upadacitinib (Rinvoq) - rheumatoid arthritis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2020 Health Canada - Drug and Health Product Register

10. Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery

Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery Immunosuppression and the Risk of Readmission and Mortality in Patients With Rheumatoid Arthritis Undergoing Hip Fracture, Abdominopelvic and Cardiac Surgery - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Ann Rheum Dis Actions . 2020 May;79(5):573-580. doi: 10.1136/annrheumdis-2019-216802. Epub 2020 Mar 24. Immunosuppression and the Risk of Readmission and Mortality in Patients With Rheumatoid Arthritis Undergoing Hip Fracture, Abdominopelvic and Cardiac Surgery , , , , , , , , Affiliations Expand Affiliations 1 Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA

2020 EvidenceUpdates

11. A randomized, double-blind, placebo-controlled clinical trial, evaluating the garlic supplement effects on some serum biomarkers of oxidative stress, and quality of life in women with rheumatoid arthritis Full Text available with Trip Pro

A randomized, double-blind, placebo-controlled clinical trial, evaluating the garlic supplement effects on some serum biomarkers of oxidative stress, and quality of life in women with rheumatoid arthritis A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Evaluating the Garlic Supplement Effects on Some Serum Biomarkers of Oxidative Stress, and Quality of Life in Women With Rheumatoid Arthritis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Int J Clin Pract Actions . 2020 Mar 11;e13498. doi: 10.1111/ijcp.13498. Online ahead of print. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Evaluating the Garlic Supplement Effects on Some Serum Biomarkers of Oxidative Stress, and Quality of Life in Women With Rheumatoid Arthritis , , Affiliations Expand

2020 EvidenceUpdates

12. Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial

Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial Two-year Cost-Effectiveness of Different COBRA-like Intensive Remission Induction Schemes in Early Rheumatoid Arthritis: A Piggyback Study on the Pragmatic Randomised Controlled CareRA Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Ann Rheum Dis Actions . 2020 May;79(5):556-565. doi: 10.1136/annrheumdis-2019-216874. Epub 2020 Apr 2. Two-year Cost-Effectiveness of Different COBRA-like Intensive Remission Induction Schemes in Early Rheumatoid Arthritis: A Piggyback Study on the Pragmatic Randomised Controlled CareRA Trial , , , , , , , Affiliations Expand Affiliations 1

2020 EvidenceUpdates

13. Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis

Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis Conventional Versus Ultrasound Treat to Target: No Difference in Magnetic Resonance Imaging Inflammation or Joint Damage Over 2 Years in Early Rheumatoid Arthritis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Rheumatology (Oxford) Actions . 2020 Jan 30;kez674. doi: 10.1093/rheumatology/kez674. Online ahead of print. Conventional Versus Ultrasound Treat to Target: No Difference in Magnetic Resonance Imaging Inflammation or Joint Damage Over 2 Years in Early Rheumatoid Arthritis , , , , , , , , , , Collaborators, Affiliations Expand Collaborators

2020 EvidenceUpdates

14. Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors Full Text available with Trip Pro

Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors Risk of Breast Cancer Before and After Rheumatoid Arthritis, and the Impact of Hormonal Factors - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health U.S (...) Permalink Copy Page navigation Ann Rheum Dis Actions . 2020 Mar 11;annrheumdis-2019-216756. doi: 10.1136/annrheumdis-2019-216756. Online ahead of print. Risk of Breast Cancer Before and After Rheumatoid Arthritis, and the Impact of Hormonal Factors , , , Affiliations Expand Affiliations 1 Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden hjalmar.wadstrom@ki.se. 2 Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet

2020 EvidenceUpdates

15. Group cognitive behavioural courses may reduce fatigue from rheumatoid arthritis. (Abstract)

Group cognitive behavioural courses may reduce fatigue from rheumatoid arthritis. The studyHewlett S, Almeida C, Ambler N, et al. Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT). Ann Rheum Dis 2019;78:465-72.Hewlett S, Almeida C, Ambler N, et al. Group cognitive behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations. Health Technol (...) Assess 2019;23:57.This project was funded by the NIHR Health Technology Assessment Programme (project number 11/112/01).To read the full NIHR Signal, go to: https://discover.dc.nihr.ac.uk/content/signal-000860/group-cognitive-behavioural-courses-may-reduce-fatigue-from-rheumatoid-arthritis.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

2020 BMJ

16. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs Full Text available with Trip Pro

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for the most recent developments in the field.An international task force considered new evidence supporting or contradicting previous recommendations and novel therapies and strategic insights based on two systematic literature

2020 EvidenceUpdates

17. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis Full Text available with Trip Pro

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis To perform a systematic literature review (SLR) concerning the safety of synthetic (s) and biological (b) disease-modifying anti rheumatic dugs (DMARDs) to inform the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis (RA).An SLR of observational studies comparing safety outcomes of any DMARD

2020 EvidenceUpdates

18. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis Full Text available with Trip Pro

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis To inform the 2019 update of the European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA).A systematic literature research (SLR) to investigate the efficacy of any disease-modifying antirheumatic drug (DMARD) (conventional synthetic (cs)DMARD, biological (b

2020 EvidenceUpdates

19. Janus Kinase Inhibitors and Biosimilars for Rheumatoid Arthritis: Effectiveness and Value

Janus Kinase Inhibitors and Biosimilars for Rheumatoid Arthritis: Effectiveness and Value ©Institute for Clinical and Economic Review, 2020 Janus Kinase Inhibitors and Biosimilars for Rheumatoid Arthritis: Effectiveness and Value Final Evidence Report and Meeting Summary January 9, 2020 Prepared for ©Institute for Clinical and Economic Review, 2020 Page i Final Evidence Report: JAK Inhibitors and Biosimilars for RA None of the above authors disclosed any conflicts of interest. DATE (...) OF PUBLICATION: January 9, 2020 How to cite this document: Tice J, Kumar V, Chapman R, Walsh J, Herron-Smith S, Cianciolo L, Bradt P, Pearson S. Janus Kinase Inhibitors and Biosimilars for Rheumatoid Arthritis. Institute for Clinical and Economic Review, January 9, 2020. https://icer-review.org/material/ra-update-evidence- report/. Jeffrey A. Tice served as the lead author for the report, led the systematic review and authorship of the comparative clinical effectiveness section, and wrote the background

2020 California Technology Assessment Forum

20. Upadacitinib (Rinvoq) - Rheumatoid arthritis

Upadacitinib (Rinvoq) - Rheumatoid arthritis Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Classified as public by the European Medicines Agency EMA/582949/2019 EMEA/H/C/004760 (...) Rinvoq (upadacitinib) An overview of Rinvoq and why it is authorised in the EU What is Rinvoq and what is it used for? Rinvoq is a medicine for treating adults with rheumatoid arthritis, a disease that causes inflammation of the joints. Rinvoq is used for moderate or severe rheumatoid arthritis that cannot be controlled well enough with disease-modifying anti-rheumatic medicines or if the patient cannot take these medicines. It can be used on its own or with methotrexate, another medicine

2020 European Medicines Agency - EPARs